Nektar Therapeutics (0UNL) Price & Analysis

0 Followers

0UNL Stock Chart & Stats

$71.82

$0.08(0.12%)

At close: Jul 30 4:00 PM EDT

$71.82

$0.08(0.12%)

Day’s Range― - ―

52-Week Range$28.70 - $109.01

Previous CloseN/A

Volume20.00

Average Volume (3M)1.15K

Market Cap

$1.95B

Enterprise Value$1.76K

Total Cash (Recent Filing)$684.34M

Total Debt (Recent Filing)$135.93M

Price to Earnings (P/E)―

Beta0.55

Next Earnings

Nov 05, 2026

EPS Estimate

-2.1

Next Dividend Ex-DateN/A

Dividend Yield6.49%

Share Statistics

EPS (TTM)-6.70

Shares Outstanding34,142,994

10 Day Avg. Volume2,432

30 Day Avg. Volume1,151

Financial Highlights & Ratios

PEG Ratio-0.36

Price to Book (P/B)7.94

Price to Sales (P/S)12.91

P/FCF Ratio-3.42

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$139.14

Price Target Upside93.74% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)-8.18

Revenue Forecast (FY)$41.88M

Bulls Say, Bears Say

Bulls Say

Strong Funded RunwayThe substantial cash balance and financing proceeds provide resources to advance multiple pivotal programs without an immediate funding requirement. A runway into Q3 2028 supports continued development through important readouts, although spending plans remain significant.

Phase 3 Pipeline AdvancementAdvancing rezpeg into pivotal trials represents meaningful clinical and strategic progress for a clinical-stage biotech. Multiple registrational programs can broaden the opportunity set and create potential future product revenue if efficacy, safety, and regulatory milestones are achieved.

Promising Durability And Safety SignalsSignals of durable efficacy and a favorable observed safety profile could differentiate rezpeg in immune-mediated diseases where response persistence and tolerability influence treatment choice. If reproduced in Phase 3, these attributes may support adoption across sizeable underserved patient populations.

Bears Say

Substantial Ongoing Cash BurnHeavy cash consumption remains a core structural risk because the company is funding expensive clinical development without broad product sales. Continued burn can reduce financial flexibility and may require additional financing before commercial revenues become available.

Contracting, Concentrated Revenue BaseNear-term revenue is modest and dependent mainly on royalty income rather than Nektar’s own commercial products. This leaves earnings exposed to collaboration economics and timing while the company remains reliant on successful rezpeg development to establish a broader recurring revenue base.

Multi-year Clinical And Regulatory Execution RiskThe principal value-creation milestones remain several years away and depend on successful trials, regulatory interactions, and eventual market adoption. Delays, unfavorable data, or changing competitive dynamics could extend losses and postpone the transition from development-stage economics to product revenue.

Nektar Therapeutics News

Nektar management to meet virtually with BTIG

Virtual Meeting to be held on October 6 hosted by BTIG. Published first on TheFly – the ultimate...

1d ago

NKTR

Nektar awarded $90M in Eli Lilly breach of contract case

Nektar (NKTR) in 2023 filed a complaint in the U.S. District Court for the Northern District of California...

2d ago

LLY

NKTR

Nektar selloff on trial brings ‘strong entry point,’ says BTIG

BTIG says that while the $90M jury award is below the $1B initial amount Nektar (NKTR) appeared to...

2d ago

LLY

NKTR

Nektar shares pressured by jury notes in Lilly case, says B. Riley

B. Riley analyst Mayank Mamtani says jury deliberations are headed to the fourth day today in Nektar’s (NKTR)...

7d ago

LLY

NKTR

Nektar price target lowered to $50 from $80 at Wedbush

Wedbush lowered the firm’s price target on Nektar (NKTR) to $50 from $80 and keeps a Neutral rating...

7d ago

LLY

NKTR

Nektar dropped as jury deliberates suit against Eli Lilly

Nektar (NKTR) shares dropped yesterday as a federal jury in San Francisco continued to deliberate the company’s breach...

7d ago

LLY

NKTR

Analyst Reiterates Buy on Nektar as Legal Overhang Clears, REZPEG Outlook Strengthens and $178 Price Target Remains Unchanged

Nektar Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst on September 25. Analyst Julian...

2d ago

NKTR

Nektar Wins $90 Million Verdict in Lilly Dispute

Nektar Therapeutics ( ($NKTR) ) has issued an announcement. In August 2023, Nektar Therapeutics filed a complaint in...

5d ago

NKTR

Nektar’s Rezpeg Trial Completion Adds a New Catalyst in Alopecia Areata

Nektar Therapeutics ($NKTR) announced an update on their ongoing clinical study. The Rezolve AA Phase 2b study, officially...

12d ago

NKTR

Nektar’s rezpegaldesleukin featured in published atopic dermatitis trial

Nektar (NKTR) announced the publication of peer-reviewed data from the 16-week induction period of REZOLVE-AD, a global, randomized,...

1M ago

NKTR

Nektar reinstated with a Neutral at JPMorgan

JPMorgan analyst Jessica Fye reinstated coverage of Nektar (NKTR) with a Neutral rating and $65 price target The...

1M ago

NKTR

Nektar Therapeutics’ Earnings Call Highlights Rezpeg Momentum

Nektar Therapeutics (($NKTR)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

NKTR

Nash Reiterates Buy on Nektar, Citing Strong Cash Position and Rezpegaldesleukin Progress; Keeps $153 Price Target Unchanged

Canaccord Genuity analyst Edward Nash reiterated a Buy rating on Nektar Therapeutics today and set a price target...

1M ago

NKTR

Nektar: Strong Cash Runway and Rezpeg Momentum Support Unchanged $185 Price Target and Buy Rating

Nektar Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Arthur He CFA...

1M ago

NKTR

0UNL FAQ

What was Nektar Therapeutics’s price range in the past 12 months?

Nektar Therapeutics lowest share price was $28.70 and its highest was $109.01 in the past 12 months.

What is Nektar Therapeutics’s market cap?

Nektar Therapeutics’s market cap is $1.95B.

When is Nektar Therapeutics’s upcoming earnings report date?

Nektar Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 36 days.

How were Nektar Therapeutics’s earnings last quarter?

Nektar Therapeutics released its earnings results on Aug 13, 2026. The company reported -$1.23 earnings per share for the quarter, beating the consensus estimate of -$1.971 by $0.741.

Is Nektar Therapeutics overvalued?

According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nektar Therapeutics pay dividends?

Nektar Therapeutics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 6.49%. See more information on Nektar Therapeutics dividends here

What is Nektar Therapeutics’s EPS estimate?

Nektar Therapeutics’s EPS estimate is -2.1.

How many shares outstanding does Nektar Therapeutics have?

Nektar Therapeutics has 34,142,994 shares outstanding.

What happened to Nektar Therapeutics’s price movement after its last earnings report?

Nektar Therapeutics reported an EPS of -$1.23 in its last earnings report, beating expectations of -$1.971. Following the earnings report the stock price went down -2.534%.

Which hedge fund is a major shareholder of Nektar Therapeutics?

Currently, no hedge funds are holding shares in GB:0UNL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Nektar Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

427.69%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

Nektar Therapeutics (0UNL) Earnings & Revenues

Historic Earnings Reports

0UNL Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call contained multiple substantial positive developments: initiation of the global Phase 3 program in atopic dermatitis, FDA-aligned registrational design for alopecia areata, strong Phase 2b signals (efficacy, durability, favorable safety), robust cash balance after a $350M offering, and encouraging market research supporting commercial potential. Offsetting these positives are expected higher R&D and G&A spend, a meaningful quarterly net loss, modest near-term revenue largely from non-cash royalties, a cash runway that covers key mid-2028 readouts but leaves limited buffer for delays, and an ongoing litigation matter. On balance the strategic, clinical, and financial highlights outweigh the risks described on the call.View all GB:0UNL earnings summaries

0UNL Stock 12 Month Forecast

Average Price Target

$139.14

▲(93.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"$28","193":"$193","69.25":"$69.3","110.5":"$110.5","151.75":"$151.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":192,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$192.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":139.14285714285714,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$139.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,69.25,110.5,151.75,193],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72,81.23076923076923,90.46153846153845,99.6923076923077,108.92307692307692,118.15384615384615,127.38461538461539,136.6153846153846,145.84615384615384,155.07692307692307,164.3076923076923,173.53846153846155,182.76923076923077,{"y":192,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72,77.16483516483517,82.32967032967034,87.49450549450549,92.65934065934066,97.82417582417582,102.98901098901098,108.15384615384615,113.31868131868131,118.48351648351648,123.64835164835165,128.8131868131868,133.97802197802196,{"y":139.14285714285714,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72,70.3076923076923,68.61538461538461,66.92307692307692,65.23076923076923,63.53846153846154,61.84615384615385,60.15384615384615,58.46153846153846,56.769230769230774,55.07692307692308,53.38461538461539,51.69230769230769,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.288,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.172,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.195,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.079,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.894,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.669,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.84,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.795,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.45,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.629,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >